FDA approves Amgen and Allergan’s Kanjinti, Herceptin biosimilar

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved Amgen and Allergan Kanjinti’s (trastuzumab-anns) for all approved indications of the reference product, Herceptin (trastuzumab) for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
In This Issue

YOU MAY BE INTERESTED IN

Login